Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Aug 1:7:124.
doi: 10.1186/1748-717X-7-124.

Early prediction of histopathological response of rectal tumors after one week of preoperative radiochemotherapy using 18 F-FDG PET-CT imaging. A prospective clinical study

Natalia Goldberg  1 , Yulia Kundel, Ofer Purim, Hanna Bernstine, Noa Gordon, Sara Morgenstern, Efraim Idelevich, Nir Wasserberg, Aaron Sulkes, David Groshar, Baruch Brenner
Affiliations

Early prediction of histopathological response of rectal tumors after one week of preoperative radiochemotherapy using 18 F-FDG PET-CT imaging. A prospective clinical study

Natalia Goldberg et al. Radiat Oncol. .

Abstract

Background: Preoperative radiochemotherapy (RCT) is standard in locally advanced rectal cancer (LARC). Initial data suggest that the tumor's metabolic response, i.e. reduction of its 18 F-FDG uptake compared with the baseline, observed after two weeks of RCT, may correlate with histopathological response. This prospective study evaluated the ability of a very early metabolic response, seen after only one week of RCT, to predict the histopathological response to treatment.

Methods: Twenty patients with LARC who received standard RCT regimen followed by radical surgery participated in this study. Maximum standardized uptake value (SUV-MAX), measured by PET-CT imaging at baseline and on day 8 of RCT, and the changes in FDG uptake (ΔSUV-MAX), were compared with the histopathological response at surgery. Response was classified by tumor regression grade (TRG) and by achievement of pathological complete response (pCR).

Results: Absolute SUV-MAX values at both time points did not correlate with histopathological response. However, patients with pCR had a larger drop in SUV-MAX after one week of RCT (median: -35.31% vs -18.42%, p = 0.046). In contrast, TRG did not correlate with ΔSUV-MAX. The changes in FGD-uptake predicted accurately the achievement of pCR: only patients with a decrease of more than 32% in SUV-MAX had pCR while none of those whose tumors did not show any decrease in SUV-MAX had pCR.

Conclusions: A decrease in ΔSUV-MAX after only one week of RCT for LARC may be able to predict the achievement of pCR in the post-RCT surgical specimen. Validation in a larger independent cohort is planned.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The histopathological appearance of representative cases of a complete responder and a non-responder (H&E, magnification X4). In the case of a complete responder (Figure 1A), the mucosa was eroded at the tumor site and there was marked fibrosis with focal microcalcifications. No residual tumor was found. In the case of a non-responder (Figure 1B), nearly no signs of response were noted (tumor regression grade [TRG] IV). Abundant tumor was found, with minimal fibrosis and regressive changes between the invasive tumor.
Figure 2
Figure 2
Distribution of SUV-max values at baseline and after one week of RCT according to histopathological response. Histopathological response was evaluated by the presence or absence of pCR (Figure 2A) or tumor regression grade (Figure 2B). Extreme values are represented by red circles.
Figure 3
Figure 3
Distribution of ΔSUV-MAX between baseline and after one week of RCT according to histopathological response. Histopathological response was evaluated by the presence or absence of pCR (Figure 3A) or tumor regression grade (Figure 3B). Extreme values are represented by red circles.
Figure 4
Figure 4
Prediction of histological response using early metabolic response.
See this image and copyright information in PMC

References

    1. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, van de Velde CJ. Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638–646. doi: 10.1056/NEJMoa010580. - DOI - PubMed
    1. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R. German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–1740. doi: 10.1056/NEJMoa040694. - DOI - PubMed
    1. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC. EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114–1123. doi: 10.1056/NEJMoa060829. - DOI - PubMed
    1. Valentini V, Coco C, Cellini N, Picciocchi A, Fares MC, Rosetto ME, Mantini G, Morganti AG, Barbaro B, Cogliandolo S, Nuzzo G, Tedesco M, Ambesi-Impiombato F, Cosimelli M, Rotman M. Ten years of preoperative chemoradiation for extraperitoneal T3 rectal cancer: Acute toxicity, tumor response, and sphincter preservation in three consecutive studies. Int J Radiat Oncol Biol Phys. 2001;51:371–383. - PubMed
    1. Capirci C, Rubello D, Chierichetti F, Crepaldi G, Fanti S, Mandoliti G, Salviato S, Boni G, Rampin L, Polico C, Mariani G. Long-term prognostic value of 18 F-FDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy. Am J Roentgenol. 2006;187:W202–W208. doi: 10.2214/AJR.05.0902. - DOI - PubMed

MeSH terms

Supplementary concepts

LinkOut - more resources